自体树突状细胞肿瘤疫苗治疗脑胶质瘤的临床初步观察

Preliminary Results of Vaccination of Glioma Patients with Autologous Dendritic Ceils Pulsed with Autologous Tumor Peptides

目的本文研究自体树突状细胞肿瘤疫苗治疗人类脑胶质瘤的临床效果,并探讨其应用前景。方法将41例病理证实的脑胶质瘤患者分为3组,试验组9人接受自体树突状细胞肿瘤疫苗治疗,阳性对照组17人接受全肿瘤组织匀浆疫苗治疗,阴性对照组15人,手术后仅接受放疗。结果随访结果显示,试验组中位数生存时间大于22个月,阳性对照组为16个月,二者均高于阴性对照组(7个月)。生存分析示3组间的生存曲线分布差异有显著性意义。结论自体树突状细胞肿瘤疫苗和全肿瘤组织匀浆疫苗可抑制脑胶质瘤的复发和进展,从而有效地延长脑胶质瘤患者的生存时间,且前者较后者具有更好的疗效,有良好的临床应用前景。

Objective To study the preliminary results of the vaccination of glioma patients with antologous dendrite cells. Methods Forty-one patients with gliomas,who underwent the operation for the gliomas,were randomly divided into three groups.Nine patients in treatment group were treated by vaccination of autologous dendritic cell pulsed with autologous tumor peptides;17 patients in positive control group were treated by vaccination of autologous tumor peptides and 15 patients in negative control group received only radiotherapy.Results The following up and survival analysis showed that the median survival time of the patients in the treatment group was above 22 months which was significantly longer (P<0.05) than that of patients in the positive control group (16 months) and the negative control group (7 months).Conclusion This clinical trial demonstrated that the autologous peptide-pulsed dendritic cell vaccine is feasible,safe,and effective for patients with gliomas.Further clinical studies of DC therapy are needed in the patients with gliomas.